vap 1

SSAO/VAP-1 Inhibitor 1 is a potent compound aimed at inhibiting SSAO/VAP-1, a protein involved in facilitating the translocation of Glucose Transport 4 (GLUT 4) to the cell membrane in adipocytes, thus playing a crucial role in glucose regulation. Additionally, in endothelial cells, this enzyme is responsible for mediating the adherence and infiltration of leukocytes, contributing to inflammatory responses. Given these mechanisms, SSAO/VAP-1 Inhibitor 1 holds considerable potential for research into treatments for inflammation, inflammation-related conditions, diabetes, and diabetes-associated diseases[1].

LJP-1586 HCl, a highly selective inhibitor of vascular adhesion protein-1 (VAP-1), exhibits antiinflammation effect by reducing adhesion molecule expression and immune cell infiltration after intracerebral hemorrhage (ICH).

Vapaliximab (2D10) is a monoclonal antibody targeting human VAP-1 [1].

PXS-4681A is a powerful, specific, and irreversible inhibitor of semicarbazide-sensitive amine oxidase (SSAO; VAP-1), with an oral activity and a Ki value of 37 nM. It exhibits exceptional selectivity towards related amine oxidases, ion channels, and seven-transmembrane domain receptors. Additionally, PXS-4681A demonstrates potent anti-inflammatory properties.

Fmoc-VAP-MMAE is a conjugate utilized in antibody-drug conjugates (ADCs), comprising a tubulin inhibitor, monomethyl auristatin E (MMAE), connected via an ADC linker, and shielded by a fluorenylmethyloxycarbonyl (Fmoc) protective group [1].

Vepalimomab, an Anti-Human AOC3 Recombinant Antibody, is a monoclonal antibody that inhibits Vascular Adhesion Protein 1 (VAP-1), exhibiting anti-inflammatory properties [1].

Timolumab (BTT1023), a fully human monoclonal antibody, selectively targets VAP-1 and has potential applications in investigating chronic inflammatory diseases [1] [2].